Clinical efficacy of Tongxinluo capsule combined with enhanced external counterpulsation in patients with ischemic cardiomyopathy and heart failure

Zhang Aiai; Liu Wei; Du Meiling; Li Feixing; Yi Mengyang; Han Wei; Song Jianying; Li Fangjiang

doi:10.3760/j.issn.1673-4777.2025.08.021

Abstract：Objective To evaluate the clinical efficacy of Tongxinluo capsule combined with enhanced external counterpulsation(EECP)in patients with ischemic cardiomyopathy and heart failure.Methods A total of 188 patients with ischemic cardiomyopathy and heart failure who were hospitalized in the Department of Cardiovascular Medicine,the First Affiliated Hospital of Hebei North University from May 2021 to June 2023 were selected.The patients were divided into control group and observation group by block randomization method,with 94 cases in each group.The control group was treated with conventional western medicine combined with EECP,and the observation group was treated with Tongxinluo capsule on the basis of the control group.Both groups were treated for 8 weeks.The traditional Chinese medicine syndrome scores,hemodynamic indicators(cardiac output,cardiac index,stroke volume),cardiac function indicators[left ventricular end systolic diameter(LVESD),left ventricular ejection fraction(LVEF),left ventricular end diastolic diameter(LVEDD)],and safety were compared between the two groups before and after treatment.Results The traditional Chinese medicine syndrome scores of the two groups at 8 weeks of treatment were lower than those before treatment,and those of the observa-tion group were lower than those of the control group[(9.4±2.3)vs(11.7±2.8)](all P＜0.05).The cardiac output,cardiac index and stroke volume of the two groups at 8 weeks of treatment were higher than those before treatment,and those of the observation group were higher than those of the control group(all P＜0.05).After 8 weeks of treatment,LVESD and LVEDD of the two groups were lower than those before treatment,and LVEF was higher than that before treatment,and LVESD and LVEDD of the observation group were lower than those of the control group,and LVEF was higher than that of the control group(all P＜0.05).During the treatment and observation period,there was no significant difference in the incidence of nausea and vomiting,insomnia,and abdominal discomfort between the two groups(all P＞0.05).Conclusion Tongxinluo capsule combined with EECP in the treatment of patients with ischemic cardiomyopathy and heart failure can improve the traditional Chinese medicine syndrome score,hemodynamics and cardiac function indexes,and has good safety.